QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Cerus Corporation (CERS)

Healthcare

No action
Fundamental
3
Sentiment
3
Technical
2

Do Nothing: chart scores 2/5 (bounce-only) — the 2026-11-09 close of 2.07 sits below SMA20 2.29, SMA50 2.41, SMA200 2.44 and the full EMA/WMA stack with MACD -0.07/-0.04 (histogram -0.02) still negative, so the bounce off 1.91 has no confirmed reversal; the pullback/oversold limit path is barred by the countertrend gate (price < SMA50 with macdLine < 0, and price below SMA200 with SMA50 < SMA200 and no reclaim), and no breakout stop qualifies because no momentum-breakout base exists — a stop above the settled 2.10 high would enter beneath the entire falling MA stack.

Analysis as of 2026-11-10· more than 2 trading days ago

Company overview

Cerus Corporation is a biotechnology firm focused on enhancing blood safety through its INTERCEPT Blood System, which neutralizes pathogens in transfusable blood components. The company offers systems for deactivating pathogens in platelets, plasma, and red blood cells, distributing globally through direct sales and distributors.

Fundamental

fair
Fundamental3
Mixed fundamentals

Cerus shows a credible turnaround with revenue growth but remains unprofitable and reliant on external funding.

Cerus is a commercial-stage blood-safety company in a real operating turnaround: total revenue grew about 16% in FY2025 and 11% over nine months of FY2026, the GAAP operating loss has shrunk from $(30.1)M in FY2023 to $(1.8)M across nine months of FY2026, debt was refinanced in June 2026 so no principal is due before 2030, and $57.7M of cash plus investments and affirmed covenant compliance back management's twelve-month sufficiency statement. It is still not self-funding — trailing net loss of roughly $(7.3)M, negative EBITDA, negative interest coverage, trailing free cash flow near zero, a large inventory build consuming cash, about 370 basis points of gross-margin compression from tariffs and FX, and roughly 5% annual dilution with a $96.8M ATM and a new shelf registration outstanding. Mixed fundamentals with real catalysts and real leverage: no distress signals in the filings, but no margin of safety either.

Sentiment

fair
Sentiment3
Conflicting catalysts

Sentiment is mixed with positive trial results but offset by dilution concerns from a new shelf registration.

Dominant catalyst is the announced 2026-11-02 positive Phase 3 RedeS topline for INTERCEPT red blood cells — the strongest-scored item in the window at +0.60 — set against a neutral-reception Q3 print (product revenue +10% with FY2026 product revenue guidance reiterated at $229M-$231M) and a fresh 2026-11-02 Form S-3 shelf that keeps dilution overhang live. The 14-day media aggregate reads mildly positive at roughly +0.11 across 13 scored items, but the sentiment delta is indeterminate because the 90-day baseline produced only one scorable item; with bullish product and sell-side legs and a bearish capital_structure leg all inside the actionable window, a moderate red-flag cap applies (conflicting catalyst signals) — severe-flag screen clean, zero regulator-confirmed investigations, no going-concern conclusion and no auditor issue.

Technical

weak
Technical2
Downtrend persists

The stock remains in a downtrend with no confirmed reversal, limiting tradable opportunities.

CERS is in a live short-term downtrend: the 2026-11-09 close of 2.07 sits below SMA20 2.29, SMA50 2.41, SMA200 2.44, EMA9 2.22, EMA21 2.29, WMA9 2.21, WMA21 2.28, DEMA14 2.19 and TEMA14 2.15, with lower highs (2.52 → 2.44 → 2.14 → 2.10) and lower lows (2.32 → 2.05 → 2.01 → 1.91) across the last four sessions. MACD has just re-crossed bearish (line -0.07 vs signal -0.04, histogram -0.02 after +0.02 on 2026-11-04) and ADX14 23.32 is rising, i.e. trend strength building downward rather than a fading decline. The sole constructive datum is the 2026-11-09 hammer (low 1.91, close 2.07, +2.48%, reclaiming the 2.025 daily VWAP) with RSI14 36.93 and Williams %R -73.77 recovering from washed-out readings — a single-bar bounce off support, not a confirmed reversal. Score 2: mostly weak/bounce-only, no qualifying long setup.

You’re looking at 2026-11-10 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.